Edition:
United States

Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

32.28USD
3:13pm EDT
Change (% chg)

$-0.29 (-0.89%)
Prev Close
$32.57
Open
$32.89
Day's High
$32.89
Day's Low
$31.98
Volume
41,950
Avg. Vol
137,125
52-wk High
$41.69
52-wk Low
$23.07

Latest Key Developments (Source: Significant Developments)

Celgene and Acceleron complete enrollment in MEDALIST, BELIEVE Phase 3 studies of luspatercept
Thursday, 1 Jun 2017 07:30am EDT 

June 1 (Reuters) - Celgene Corp :Celgene and Acceleron complete target enrollment in the medalist and believe Phase 3 studies of luspatercept in myelodysplastic syndromes and beta-thalassemia.Acceleron Pharma Inc - ‍companies expect to report top-line results from Phase 3 studies in mid-2018​.Acceleron Pharma Inc - ‍medalist phase 3 trial has enrolled 210 patients with lower-risk mds​.Acceleron Pharma Inc - ‍believe phase 3 trial has enrolled 300 patients with transfusion dependent beta-thalassemia​.  Full Article

Acceleron Pharma qtrly loss per share $0.66
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Acceleron Pharma Inc :Acceleron pharma reports first quarter 2017 operational and financial results.Acceleron pharma inc - collaboration revenue for q1 was $3.7 million.Acceleron pharma inc qtrly loss per share $0.66.Acceleron pharma inc - plans to initiate luspatercept phase 3 trial in first-line, lower-risk mds in early 2018.  Full Article

Acceleron announces management change
Tuesday, 2 May 2017 04:30pm EDT 

May 2 (Reuters) - Acceleron Pharma Inc ::Acceleron announces management change.Acceleron Pharma Inc - Steven Ertel, due to medical reasons, will transition from his role as executive vice president and chief operating officer.Acceleron Pharma Inc - Ertel was recently diagnosed with amyotrophic lateral sclerosis.  Full Article

Acceleron says enrolment for late stage studies now expected to be completed in Q2
Thursday, 27 Apr 2017 07:35am EDT 

April 27 (Reuters) - Acceleron Pharma Inc :Acceleron provides clinical development updates on luspatercept program.Acceleron pharma inc says enrollment in MEDALIST and BELIEVE phase 3 studies now expected to be completed in q2 2017."we now look forward to reporting topline results from medalist and believe phase 3 studies in mid-2018".Acceleron pharma inc says acceleron and celgene also plan to initiate a third phase 3 trial of luspatercept.New phase 3 trial of luspatercept is expected to be initiated in early 2018.  Full Article

Acceleron to initiate phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease
Thursday, 16 Mar 2017 07:00am EDT 

Acceleron Pharma Inc - : Acceleron announces plans to initiate a phase 2 trial of ACE-083 in charcot-marie-tooth neuromuscular disease and host educational webinar .Second phase 2 study for ACE-083 expected to begin 2H 2017.  Full Article

Acceleron Q4 loss per share $0.51
Wednesday, 1 Mar 2017 07:00am EST 

Acceleron Pharma Inc : Acceleron reports fourth quarter and year ended 2016 operational and financial results . Acceleron Pharma Inc says outlined plans to initiate several new clinical trials in 2017 . Acceleron Pharma Inc says luspatercept phase 3 trials to complete enrollment in both MDS and beta-thalassemia trials in 2H 2017 . Qtrly loss per share $0.51 .Qtrly collaboration revenue $3.4 million versus $3.8 million.  Full Article

Acceleron Pharma reports Q3 financial and operational results
Thursday, 3 Nov 2016 04:05pm EDT 

Acceleron Pharma Inc : Acceleron Pharma Inc qtrly earnings per share $0.55 .Acceleron Pharma reports third quarter 2016 financial and operational results.  Full Article

Acceleron:Habib Dable named president and ceo
Tuesday, 27 Sep 2016 04:01pm EDT 

Acceleron Pharma Inc : Acceleron announces retirement of John Knopf as president and ceo; Habib Dable named as successor . Habib Dable appointed as president and ceo .Acceleron Pharma Inc says Habib Dable will assume ceo role effective December 1, 2016.  Full Article

Acceleron Pharma Q2 loss per share $0.59
Thursday, 4 Aug 2016 07:00am EDT 

Acceleron Pharma Inc : Acceleron Pharma reports second quarter 2016 financial and operational results . Q2 loss per share $0.59 .Q2 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Acceleron announces ACE-083 phase 1 results
Friday, 8 Jul 2016 07:00am EDT 

Acceleron Pharma Inc : Announces ACE-083 phase 1 results at 14th International Congress On Neuromuscular Diseases . ACE-083 increased muscle volume of tibialis anterior muscle by 8.9% in healthy volunteers .Acceleron intends to advance ACE-083 into a phase 2 clinical trial in patients with FSHD in second half of 2016..  Full Article

BRIEF-Acceleron announces top-line results from dart phase 2 study of dalantercept

* Acceleron announces top-line results from dart phase 2 study of dalantercept in advanced renal cell carcinoma